|Systematic (IUPAC) name|
|Pregnancy cat.||B3 (AU) C (US)|
|Legal status||Prescription Only (S4) (AU) ℞-only (CA) POM (UK) ℞-only (US)|
|Routes||Oral and i.v. (US), Oral only (UK)|
|Bioavailability||55%, maximal if taken with full meal|
|(what is this?)|
Itraconazole has a broader spectrum of activity than fluconazole (but not as broad as voriconazole or posaconazole). In particular, it is active against Aspergillus, which fluconazole is not. It is also licensed for use in blastomycosis, sporotrichosis, histoplasmosis, and onychomycosis. Itraconazole is over 99% protein-bound and has virtually no penetration into cerebrospinal fluid. Therefore, it should never be used to treat meningitis or other central nervous system infections. According to the Johns Hopkins Abx Guide, it has "negligible CSF penetration, however treatment has been successful for cryptococcal and coccidioidal meningitis".
Itraconazole has also recently been explored as an anticancer agent for patients with basal cell carcinoma, non-small cell lung cancer, and prostate cancer. For example, in a phase II study involving men with advanced prostate cancer, high-dose itraconazole (600 mg/day) was associated with significant PSA responses and a delay in tumor progression. Itraconazole also showed activity in a phase II trial in men with non-small cell lung cancer when it was combined with the chemotherapy agent, pemetrexed.
The mechanism of action of itraconazole is the same as the other azole antifungals: it inhibits the fungal-mediated synthesis of ergosterol. Because of its ability to inhibit cytochrome P450 3A4 CC-3, caution should be used when considering interactions with other medications.
Itraconazole is pharmacologically distinct from other azole antifungal agents in that it is the only inhibitor in this class that has been shown to inhibit both the hedgehog signaling pathway and angiogenesis. These distinct activities are unrelated to inhibition of the cytochrome P450 lanosterol 14 alpha-demethylase and the exact molecular targets responsible remain unidentified. Functionally, the antiangiogenic activity of itraconazole has been shown to be linked to inhibition of glycosylation, VEGFR2 phosphorylation, trafficking, and cholesterol biosynthesis pathways. Evidence suggests the structural determinants for inhibition of hedgehog signaling by itraconazole are recognizably different from those associated with antiangiogenic activity.
The intravenous preparation is no longer available in the US as of October 11, 2007 per Ortho-Biotech Professional Letter but may be available in other countries. Itraconazole has relatively low bioavailability after oral administration, especially when given in capsule form on an empty stomach. The capsule form is a molecular dispersion of itraconazole in amorphous HPMC polymer. The fast-dissolving polymer targets a supersaturated solution of itraconazole from which enhanced absorption can be expected. Recently, itraconazole was found to contribute to the formation of nanofibers in certain simulated intestinal fluids. These nanofibers have a uniform width of 12 nm and a length up to several micrometers. The oral solution is better absorbed. The cyclodextrin contained in the oral solution can cause an osmotic diarrhea, and if this is a problem, then half the dose can be given as oral solution and half as capsule to reduce the amount of cyclodextrin given. Itraconazole capsules should always be taken with food, as this improves absorption. Itraconazole oral solution should be taken an hour before food, or two hours after food (and likewise if a combination of capsules and oral solution are used). Itraconazole may be taken with orange juice or cola, as absorption is also improved by acid. Absorption of itraconazole is impaired when taken with an antacid, H2-blocker or proton pump inhibitor.
The following drugs should not be taken with itraconazole:
- cisapride (Propulsid);
- dofetilide (Tikosyn);
- nisoldipine (Sular);
- pimozide (Orap);
- quinidine (Quinaglute, Quinidex, Quin-Release);
- lovastatin (Altocor, Altoprev, Mevacor) or simvastatin (Zocor);
- midazolam (Versed) or triazolam (Halcion);
- ergot medicines such as dihydroedrgotamine (DHE 45, Migranal), ergonavine (Ergotrate), ergotamine (Ergomar, Cafergot, Ercaf, Migergot), or methylergonovine (Methergine).
Itraconazole is a relatively well-tolerated drug (although not as well tolerated as fluconazole or voriconazole) and the range of adverse effects it produces is similar to the other azole antifungals.
- Elevated alanine aminotransferase levels are found in 4% of people taking itraconazole
- "Small but real risk" of developing congestive heart failure
- Liver failure, sometimes fatal
The cyclodextrin used to make the syrup preparation can cause diarrhea. Side effects that may indicate a greater problem include:
- abdominal pain
- loss of appetite
- yellow skin (jaundice)
- yellow eyes
- dark urine
- pale stool
Itraconazole is produced as blue 22 mm (0.87 in) capsules with tiny 1.5 mm (0.059 in) blue pellets inside. Each capsule contains 100 mg and is usually taken twice a day at twelve hour intervals. The Sporanox brand of itraconazole has been developed and marketed by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson. The three-layer structure of these blue capsules are complex because itraconazole is insoluble and is sensitive to pH. The complicated procedure not only requires a specialized machine to create it, but also the method used has manufacturing problems. Also, the pill is quite large, making it difficult for many patients to swallow. Parts of the processes of creating Sporanox were discovered by the Korean Patent Laid-open No. 10-2001-2590. The tiny blue pellets contained in the capsule are manufactured in Beerse, Belgium.
- Gilbert DN, Moellering, RC, Eliopoulos GM, Sande MA (2006). The Sanford Guide to antimicrobial therapy. ISBN 1-930808-30-5.[page needed]
- Pham, P; Bartlett, JG (2007-07-24). "Itraconazole". Johns Hopkins.
- "Search results for Itraconazole". ClinicalTrials.gov. U.S. National Institutes of Health.
- Aftab, BT; Dobromilskaya, I; Liu, JO; Rudin, CM. "Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer" (PDF). Cancer Research 71 (21): 6764–6772. doi:10.1158/0008-5472.CAN-11-0691. PMC 3206167. PMID 21896639.
- Antonarakis, ES; Heath, EI; Smith, DC; Rathkopf, D; Blackford, AL; Danila, DC; King, S; Frost, A; Ajiboye, AS; Zhao, M; Mendonca, J; Kachhap, SK; Rudek, MA; Carducci, MA (2013). "Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer" (PDF). The Oncologist 18 (2): 163–173. doi:10.1634/theoncologist.2012-314. PMID 23340005.
- Rudin, CM; Brahmer, JR; Juergens, RA; Hann, CL; Ettinger, DS; Sebree, R; Smith, R; Aftab, BT; Huang, P; Liu, JO (May 2013). "Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer". Journal of Thoracic Oncology 8 (5): 619–623. doi:10.1097/JTO.0b013e31828c3950. PMID 23546045.
- Kim, James; Tang, Jean Y.; Gong, Ruoyu et al. (2010). "Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth". Cancer Cell 17 (4): 388–99. doi:10.1016/j.ccr.2010.02.027. PMID 20385363.
- Kim, J; Aftab, BT; Tang, Jean Y.; Kim, PB; Lee, CM; Rezaee, Melika; Kim, Jynho; Chen, Baozhi; King, Emily M.; Borodovsky, Alexandra; Riggins, Gregory J.; Epstein Jr, Ervin H.; Beachy, Philip A.; Rudin, Charles M. (2013). "Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists". Cancer Cell 23 (1): 23–34. doi:10.1016/j.ccr.2012.11.017. PMC 3548977. PMID 23291299.
- Chong, Curtis R.; Xu, Jing; Lu, Jun; Bhat, Shridhar; Sullivan Jr, David J.; Liu, Jun O. (2007). "Inhibition of Angiogenesis by the Antifungal Drug Itraconazole". ACS Chemical Biology 2 (4): 263–70. doi:10.1021/cb600362d. PMID 17432820.
- Aftab, B. T.; Dobromilskaya, I.; Liu, J. O.; Rudin, C. M. (2011). "Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer". Cancer Research 71 (21): 6764–72. doi:10.1158/0008-5472.CAN-11-0691. PMC 3206167. PMID 21896639.
- Xu, J.; Dang, Y.; Ren, Y. R.; Liu, J. O. (2010). "Cholesterol trafficking is required for mTOR activation in endothelial cells". Proceedings of the National Academy of Sciences 107 (10): 4764–9. doi:10.1073/pnas.0910872107. PMC 2842052. PMID 20176935.
- Shi, Wei; Nacev, Benjamin A.; Aftab, Blake T.; Head, Sarah; Rudin, Charles M.; Liu, Jun O. (2011). "Itraconazole Side Chain Analogues: Structure–Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling". Journal of Medicinal Chemistry 54 (20): 7363–74. doi:10.1021/jm200944b. PMC 3307530. PMID 21936514.
- Mellaerts, Randy; Aerts, Alexander; Caremans, Tom P.; Vermant, Jan; Van Den Mooter, Guy; Martens, Johan A.; Augustijns, Patrick (2010). "Growth of Itraconazole Nanofibers in Supersaturated Simulated Intestinal Fluid". Molecular Pharmaceutics 7 (3): 905–13. doi:10.1021/mp900300j. PMID 20232903.
- "The Safety of Sporanox Capsules and Lamisil Tablets for the Treatment of Onychomycosis". FDA Public Health Advisory. May 9 2001. Archived from the original on 2009-05-28. Retrieved 2006-08-10.
- Composition comprising Itraconazole for oral administration. 2004. Fresh Patents.com. 26 October 2006.
- Sporanox (Itraconazole Capsules). June 2006. Janssen. 26 October 2006
- General pharmacologic information about itraconazole, National Institutes of Health
- Itraconazole Oral Route, Mayo Clinic